Core One Labs Inc (OTC:CLABF) Stock On Watchlist After Latest News
There are certain sectors that have emerged in recent years and have quickly become the source of significant interest from investors. One such field is psychedelics, and Core One Labs Inc. (OTC:CLABF) is currently involved in that space. It is also involved with neuroscience.
On December 1, the company made a major new announcement with regards to positive results from the first round of the Stage 2 animal model studies that had taken place in collaboration with the Universitat de Barcelona. The studies had been conducted on behalf of Akome Biotechnologies Inc., the company’s fully owned subsidiary unit.
The company noted in a press release this past Friday that the results from the study had been positive and demonstrated potential to perform better than the current treatments for ailments like Parkinson’s and Alzheimer’s. It was a major new milestone for the company and also signified an important step in its work on the development of innovative alternative treatments for widely occurring neurodegenerative diseases.
The Chief Executive Officer of Core One Labs, Joel Shacker, provided a statement about the latest development. He called the latest results extraordinary and noted that they underscored the strong commitment of the company to taking the fields of neuroscience and psychedelics forward. He went on to note that transformative therapies for neurodegenerative diseases were rising as the company continued to move along its path.
That aforementioned path included proving the potential of the proprietary bio-compounds of Core One Labs and the combination of the same with psychedelic compounds to treat such diseases. The findings from the study had apparently led to a significant sense of optimism among the core research team at the company. That led to the decision to start further Stage 2 studies soon. It may be a good time to keep an eye on the Core One Labs stock today.
